Genomic evolution shapes prostate cancer disease type
dc.contributor.author | Woodcock, D. J. | en |
dc.contributor.author | Sahli, A. | en |
dc.contributor.author | Teslo, R. | en |
dc.contributor.author | Bhandari, V. | en |
dc.contributor.author | Gruber, A. J. | en |
dc.contributor.author | Ziubroniewicz, A. | en |
dc.contributor.author | Gundem, G. | en |
dc.contributor.author | Xu, Y. | en |
dc.contributor.author | Butler, A. | en |
dc.contributor.author | Anokian, E. | en |
dc.contributor.author | Pope, B. J. | en |
dc.contributor.author | Jung, C. H. | en |
dc.contributor.author | Tarabichi, M. | en |
dc.contributor.author | Dentro, S. C. | en |
dc.contributor.author | Farmery, J. H. R. | en |
dc.contributor.author | Van Loo, P. | en |
dc.contributor.author | Warren, A. Y. | en |
dc.contributor.author | Gnanapragasam, V. | en |
dc.contributor.author | Hamdy, F. C. | en |
dc.contributor.author | Bova, G. S. | en |
dc.contributor.author | Foster, C. S. | en |
dc.contributor.author | Neal, D. E. | en |
dc.contributor.author | Lu, Y. J. | en |
dc.contributor.author | Kote-Jarai, Z. | en |
dc.contributor.author | Fraser, M. | en |
dc.contributor.author | Bristow, Robert G | en |
dc.contributor.author | Boutros, P. C. | en |
dc.contributor.author | Costello, A. J. | en |
dc.contributor.author | Corcoran, N. M. | en |
dc.contributor.author | Hovens, C. M. | en |
dc.contributor.author | Massie, C. E. | en |
dc.contributor.author | Lynch, A. G. | en |
dc.contributor.author | Brewer, D. S. | en |
dc.contributor.author | Eeles, R. A. | en |
dc.contributor.author | Cooper, C. S. | en |
dc.contributor.author | Wedge, David C | en |
dc.date.accessioned | 2024-06-27T07:21:10Z | |
dc.date.available | 2024-06-27T07:21:10Z | |
dc.date.issued | 2024 | en |
dc.identifier.citation | Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, et al. Genomic evolution shapes prostate cancer disease type. Cell genomics. 2024 Mar 13;4(3):100511. PubMed PMID: 38428419. Pubmed Central PMCID: PMC10943594. Epub 2024/03/02. eng. | en |
dc.identifier.pmid | 38428419 | en |
dc.identifier.doi | 10.1016/j.xgen.2024.100511 | en |
dc.identifier.uri | http://hdl.handle.net/10541/626986 | |
dc.description.abstract | The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.xgen.2024.100511 | en |
dc.title | Genomic evolution shapes prostate cancer disease type | en |
dc.type | Article | en |
dc.contributor.department | Division of Cancer Sciences, Health and Medicine, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; CRUK Manchester Institute, University of Manchester, Manchester, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK. | en |
dc.identifier.journal | Cell Genomics | en |
dc.description.note | en] | |
refterms.dateFOA | 2024-07-01T14:43:15Z |